Thermo Fisher Scientific acquires Qiagen
Thermo Fisher Scientific acquires Qiagen
… Qiagen Acquired By Thermo Fisher Scientific …


Thermo Fisher Scientific advances further into genetic testing

John G. Baresky

A global company with a bio scientific focus

Thermo Fisher Scientific (TFS) moves deeper into the genetic testing market sector with its purchase of Qiagen. Qiagen (NYSE: QGEN) specializes in sample and assay technologies used in academic and pharmaceutical research, applied testing, molecular diagnostics, oncology plus other clinical and scientific applications.

Qiagen shareholders net a decent premium on the deal

With its official main base in Venlo, Limburg, Netherlands but primary operating headquarters in Hilden, Germany, Qiagen generates just under $1.2 billion in annual sales. Stockholders reportedly will receive a 23% premium. As a timely coincidence to world events, Qiagen has a coronavirus virus test on the market that it is selling to China.

Thermo Fisher Scientific continues to build its advanced global bioscience business

TFS (NYSE: TMO) is a healthcare conglomerate with substantial lines of clinical disposables, diagnostic equipment, laboratory instrumentation, reagents, software plus medical research technology solutions and services. TFS is a respected competitor and very well known to its academic, government, healthcare provider organization, life science and pharmaceutical clients.

Primary rivals to Thermo Fisher Scientific in core as well as genetic research lines include:

  • Abbott
  • Agilent Technologies
  • BGI Group
  • Bruker
  • Danaher
  • Eurofins Scientific
  • Harvard Bioscience
  • Illumina
  • Macrogen
  • PerkinElmer
  • PierianDx
  • Roche

A successful healthcare leader with multiple capabilities

TFS is based in Waltham, MA and generates over $24 billion in sales. They operate various business units and divisions, these are the main ones:

  • Applied Biosystems
  • Fisher Scientific
  • Invitrogen
  • Thermo Scientific
  • Unity Lab Services

While TFS may choose to keep Qiagen as a separate business unit, its product lines align well with the TFS’ Applied Biosystems business unit and may be integrated into the unit to minimize redundancies.

Thank you for reading this story

Learn more about the healthcare industry; read my articles about its medical and business trends, content marketing and digital strategy, brand and product management, consumer wellness, managed care and market access strategy.

About me

Hi, my name is John Baresky and I have over 25 years of experience working in the healthcare industry.

I have been developing and sharing important information with physicians, nurses, pharmacists and other clinicians plus consumers, patients, healthcare business professionals, investors and other stakeholders throughout my career. Healthcare is a vast industry. I craft its array of clinical, business, academic, technical, and consumer topics into precise message content and stories quickly understood and immediately useful.

The content I write aligns with your organization’s voice, SEO elements and marketplace; it establishes trust in your company and recognized value in its products and services. I can help you and your content marketing create the customer bond that grows revenue.

Visit and connect with me





Bare Sky Marketing — Healthcare Content Writing

Written by

Healthcare content writing services for business, medical, consumer, patient, digital, investor, marketing, news information

More From Medium

Also tagged Content Writing

Also tagged Content Writing

Freelance Market After the Pandemic


Top on Medium

Top on Medium

Welcome to a place where words matter. On Medium, smart voices and original ideas take center stage - with no ads in sight. Watch
Follow all the topics you care about, and we’ll deliver the best stories for you to your homepage and inbox. Explore
Get unlimited access to the best stories on Medium — and support writers while you’re at it. Just $5/month. Upgrade